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and placebo was also signiﬁcant (p < 0.001) with the shortest times
observed with diclofenac-N. Treatment-emergent AEs were similar across
treatment groups with similar rates in subjects treated with placebo
(52.9%), diclofenac-N 35mg (60.8%) and diclofenac-N 18mg (55.1%).
Conclusions: An investigational, proprietary, nano-formulated, lower
dose, oral diclofenac demonstrated good efﬁcacy, onset of action, and
tolerability. As suggested by this phase-2 clinical trial, use of this lower
dose formulation could maintain efﬁcacy, shorten onset of action, and
possibly result in an improved tolerability proﬁle for patients with acute
arthritic pain.
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THE APPLICATION OF PLATELET-RICH PLASMA IN EARLY
OSTEOARTHRITIS OF KNEE
S-J. Jang. Kosin Univ. Gospel Hosp., Busan, Korea, Republic of
Purpose: Platelet-rich plasma (PRP) is a natural concentrate of
autologous blood growth factors experimented in different ﬁelds of
medicine in order to test its potential to enhance tissue regeneration,
and so emerged as a treatment option for tendinopathies and chronic
wounds. In addition to release of growth factors, PRP also promotes
concentrated anti-inﬂammatory signals including interleukin-1a, which
has been a focus of emerging treatments for osteoarthritis. The
primary objective is to compare a single, intra-articular injection of
platelet-rich plasma (PRP) with hyruan injection in patients with early
osteoarthritis of knee and to assess the clinical efﬁcacy and safety of
intra-articular platelet-rich plasma (PRP) injection in patients with low
degree osteoarthritis (OA) of the knee.
Methods: Between June 2008 and October 2010, we reviewed the
results of 86 consecutive primary osteoarthritic patients underwent
intra-articular injection of PRP.In a group of early osteoarthritis patients,
inclusion criteria was set to those who were able to be followed up for
at least 6 months and showed as Kellgren-Lawrence grade I on simple
radiograph or MRI, and exclusion criteria was set as severe obesity,
infection, immunosuppressed patients, advanced osteoarthritis(K-L grade
I, II, III), and severe deformity. PRP was injected once, in principle. Also,
to compare the effects of PRP, hyruan injection was performed in 21
cases during the same period in a same target group, and the effect
was compared by perfoming 3 times in an interval of 1 week. Results
were evaluated at 4, 8, 12, 18, 24 weeks post-injection using radiologic
study, visual analogue scale (VAS) and international knee documentation
committee (IKDC) score for functional score.
Results: According to VAS, the mean preoperative scale was 8.2 (range
7–10) and the mean postoperative scale was 3.2 (range 1–4) and 2.9
(range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
Conclusions: According to VAS, the mean preoperative scale was 8.2
(range 7–10) and the mean postoperative scale was 3.2 (range 1–4) and
2.9 (range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
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A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A
NOVEL, PROPRIETARY, NANO-FORMULATED ORAL INDOMETHACIN
G. Manvelian1, S. Daniels2. 1Independent Clinical Res. Consultant, Poway,
CA, USA; 2Premier Res. Group, Austin, TX, USA
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
medication taken for acute pain relief. Indomethacin has a long-
established efﬁcacy and safety proﬁle yet can have a variable and
somewhat slow onset of action. Indomethacin also has the potential
for gastrointestinal adverse events (AEs), suggesting the need for a
new formulation which can safely provide fast onset of acute pain
relief. Our objective was to evaluate the analgesic efﬁcacy and safety
of an investigational, proprietary, nano-formulated, oral indomethacin
compared with placebo in subjects with acute dental pain.
Methods: This was a phase-2, multicenter, randomized, double-blind,
single-dose, parallel-group, placebo-controlled study. In total, 203
subjects were enrolled who: were 18–50 years of age, had extraction
of ≥2 third molars, and experienced moderate to severe pain intensity
within 6 hours after surgery. Subjects received either nano-formulated
indomethacin 20mg, 40mg, or placebo. The primary efﬁcacy variable
was the sum of total pain relief (TOTPAR) over 8 hours (TOTPAR-8).
Higher scores indicated better pain relief.
Results: Nano-formulated indomethacin was signiﬁcantly (p< 0.001)
better than placebo for TOTPAR-8 (mean; 95% CI): 40mg (12.56; 2.64);
20mg (10.79; 2.66); placebo (3.02; 2.64). Nano-formulated indomethacin
was also signiﬁcantly (p < 0.001) better than placebo for TOTPAR-4
(mean; 95% CI): 40mg (6.16; 4.78); 20mg (5.47; 4.61); placebo (1.63;
2.83). The difference in time to onset of analgesia between each
treatment and placebo was also signiﬁcant (p < 0.001). Treatment-
emergent AEs occurred less often in subjects treated with nano-
formulated indomethacin 20mg (38.0%) than those treated with nano-
formulated indomethacin 40mg (51.0%) or placebo (56.9%).
Conclusions: A proprietary, nano-formulated, lower dose, oral
indomethacin demonstrated good efﬁcacy, onset of action, and
tolerability. The ability to utilize a lower dose and maintain efﬁcacy
could result in an improved tolerability and safety proﬁle and is in line
with the FDA directive to use the lowest effective dose for the shortest
duration.
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CLINICAL EVALUATION OF A HERBAL FORMULATION, RHULIEF™,
IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS
B. Antony1, R. Kizhakedath2, M. Benny1, B.T. Kuruvilla1. 1Arjuna Natural
Extracts Ltd., Aluva, India; 2Anugraha Med. Ctr., Kochi, India
Purpose: The study was conducted to evaluate the efﬁcacy, safety and
tolerability of Rhulief™, a unique mixture of acetyl boswellic acids
with acetyl 11-keto beta boswellic acid (AKBA) content of 10% w/w
and BCM 95®, a composition of curcumin which is about 7 times
more bioavailable than conventional curcumin, compared with non
steroidal anti-inﬂammatory drug, Celecoxib in the management of knee
Osteoarthritis.
Methods: Fifty four subjects were screened, 30 subjects were enrolled
and 28 completed the study. Subjects of both sexes aged 18 to
65 years who were medically stable with moderate form of osteoarthritis
evidenced by narrowing of the medial joint space with swelling were
randomized into two groups and were treated for a period of 12 weeks.
Gr I: Oral administration of Rhulief™ 500mg capsule twice daily
Gr II: Oral administration of Celecoxib 100mg capsule twice daily
Subjects with long standing and severe form of osteoarthritis, persons
with history of rheumatoid or reactive arthritis and signiﬁcant systemic
diseases were excluded from the study. Symptom scoring and clinical
examination were done during their each visit to ﬁnd out the efﬁcacy of
the drug. Safety of the drug was assessed by recording the liver function
test, renal function test and haemogram.
Results: The results of the symptom scoring revealed that there was a
signiﬁcant (p < 0.05) improvement in pain scores within the groups over a
period of 12 weeks and the improvement was more with Gr I. Signiﬁcant
(p < 0.05) improvement in walking distance and joint line tenderness
were also observed within the groups and the effects were greater with
Gr I. Statistically signiﬁcant difference between range of movements
were observed within both the groups (p < 0.05). The differences in
range of movements were comparable in both groups and there was
no signiﬁcant change between the two groups. Vital signs, haemogram,
liver function test and renal function test were not adversely modiﬁed by
Rhulief™. The results of the present study concluded that the treatment
was well-tolerated and did not produce any adverse effect in patients.
Conclusions: Rhulief™ at 500mg twice a day was better than Celecoxib
100mg twice daily in symptom scoring and clinical examination. It was
equally effective as Celecoxib in alleviating crepitus and range of joint
movements. The drug was well tolerated and no dose-related toxicity
was found. Efﬁcacy and tolerability of Rhulief™ used in the current
